Benzinga | Oct 14, 2021 05:56AM EDT

Morgan Stanley Downgrades Neurocrine Biosciences to Equal-Weight, Announces $112 Price Target

Morgan Stanley analyst Jeffrey Hung downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Overweight to Equal-Weight and announces $112 price target.